Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.

You may also be interested in...

Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars

Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.

Merck Makes Hepatitis C A Priority

Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.

Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build

WASHINGTON - In the latest announcement from Big Pharma about going local in Russia, Pfizer Inc. said June 29 that it had signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts